Cirrhosis is associated with lower serological responses to COVID-19 vaccines in patients with chronic liver disease
© 2023 The Authors..
Background & Aims: The response of patients with chronic liver disease (CLD) to COVID-19 vaccines remains unclear. Our aim was to assess the humoral immune response and efficacy of two-dose COVID-19 vaccines among patients with CLD of different aetiologies and disease stages.
Methods: A total of 357 patients were recruited in clinical centres from six European countries, and 132 healthy volunteers served as controls. Serum IgG (nM), IgM (nM), and neutralising antibodies (%) against the Wuhan-Hu-1, B.1.617, and B.1.1.529 SARS-CoV-2 spike proteins were determined before vaccination (T0) and 14 days (T2) and 6 months (T3) after the second-dose vaccination. Patients fulfilling inclusion criteria at T2 (n = 212) were stratified into 'low' or 'high' responders according to IgG levels. Infection rates and severity were collected throughout the study.
Results: Wuhan-Hu-1 IgG, IgM, and neutralisation levels significantly increased from T0 to T2 in patients vaccinated with BNT162b2 (70.3%), mRNA-1273 (18.9%), or ChAdOx1 (10.8%). In multivariate analysis, age, cirrhosis, and type of vaccine (ChAdOx1 > BNT162b2 > mRNA-1273) predicted 'low' humoral response, whereas viral hepatitis and antiviral therapy predicted 'high' humoral response. Compared with Wuhan-Hu-1, B.1.617 and, further, B.1.1.529 IgG levels were significantly lower at both T2 and T3. Compared with healthy individuals, patients with CLD presented with lower B.1.1.529 IgGs at T2 with no additional key differences. No major clinical or immune IgG parameters associated with SARS-CoV-2 infection rates or vaccine efficacy.
Conclusions: Patients with CLD and cirrhosis exhibit lower immune responses to COVID-19 vaccination, irrespective of disease aetiology. The type of vaccine leads to different antibody responses that appear not to associate with distinct efficacy, although this needs validation in larger cohorts with a more balanced representation of all vaccines.
Impact and Implications: In patients with CLD vaccinated with two-dose vaccines, age, cirrhosis, and type of vaccine (Vaxzevria > Pfizer BioNTech > Moderna) predict a 'lower' humoral response, whereas viral hepatitis aetiology and prior antiviral therapy predict a 'higher' humoral response. This differential response appears not to associate with SARS-CoV-2 infection incidence or vaccine efficacy. However, compared with Wuhan-Hu-1, humoral immunity was lower for the Delta and Omicron variants, and all decreased after 6 months. As such, patients with CLD, particularly those older and with cirrhosis, should be prioritised for receiving booster doses and/or recently approved adapted vaccines.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
JHEP reports : innovation in hepatology - 5(2023), 5 vom: 20. Mai, Seite 100697 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Simão, André Lopes [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 vaccine |
|---|
| Anmerkungen: |
Date Revised 17.04.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.jhepr.2023.100697 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353510637 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353510637 | ||
| 003 | DE-627 | ||
| 005 | 20231226060152.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jhepr.2023.100697 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1178.xml |
| 035 | |a (DE-627)NLM353510637 | ||
| 035 | |a (NLM)36844943 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Simão, André Lopes |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cirrhosis is associated with lower serological responses to COVID-19 vaccines in patients with chronic liver disease |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 17.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Authors. | ||
| 520 | |a Background & Aims: The response of patients with chronic liver disease (CLD) to COVID-19 vaccines remains unclear. Our aim was to assess the humoral immune response and efficacy of two-dose COVID-19 vaccines among patients with CLD of different aetiologies and disease stages | ||
| 520 | |a Methods: A total of 357 patients were recruited in clinical centres from six European countries, and 132 healthy volunteers served as controls. Serum IgG (nM), IgM (nM), and neutralising antibodies (%) against the Wuhan-Hu-1, B.1.617, and B.1.1.529 SARS-CoV-2 spike proteins were determined before vaccination (T0) and 14 days (T2) and 6 months (T3) after the second-dose vaccination. Patients fulfilling inclusion criteria at T2 (n = 212) were stratified into 'low' or 'high' responders according to IgG levels. Infection rates and severity were collected throughout the study | ||
| 520 | |a Results: Wuhan-Hu-1 IgG, IgM, and neutralisation levels significantly increased from T0 to T2 in patients vaccinated with BNT162b2 (70.3%), mRNA-1273 (18.9%), or ChAdOx1 (10.8%). In multivariate analysis, age, cirrhosis, and type of vaccine (ChAdOx1 > BNT162b2 > mRNA-1273) predicted 'low' humoral response, whereas viral hepatitis and antiviral therapy predicted 'high' humoral response. Compared with Wuhan-Hu-1, B.1.617 and, further, B.1.1.529 IgG levels were significantly lower at both T2 and T3. Compared with healthy individuals, patients with CLD presented with lower B.1.1.529 IgGs at T2 with no additional key differences. No major clinical or immune IgG parameters associated with SARS-CoV-2 infection rates or vaccine efficacy | ||
| 520 | |a Conclusions: Patients with CLD and cirrhosis exhibit lower immune responses to COVID-19 vaccination, irrespective of disease aetiology. The type of vaccine leads to different antibody responses that appear not to associate with distinct efficacy, although this needs validation in larger cohorts with a more balanced representation of all vaccines | ||
| 520 | |a Impact and Implications: In patients with CLD vaccinated with two-dose vaccines, age, cirrhosis, and type of vaccine (Vaxzevria > Pfizer BioNTech > Moderna) predict a 'lower' humoral response, whereas viral hepatitis aetiology and prior antiviral therapy predict a 'higher' humoral response. This differential response appears not to associate with SARS-CoV-2 infection incidence or vaccine efficacy. However, compared with Wuhan-Hu-1, humoral immunity was lower for the Delta and Omicron variants, and all decreased after 6 months. As such, patients with CLD, particularly those older and with cirrhosis, should be prioritised for receiving booster doses and/or recently approved adapted vaccines | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 vaccine | |
| 650 | 4 | |a Chronic liver disease | |
| 650 | 4 | |a Cirrhosis | |
| 650 | 4 | |a Humoral immunity | |
| 650 | 4 | |a SARS-CoV-2 | |
| 700 | 1 | |a Palma, Carolina Santos |e verfasserin |4 aut | |
| 700 | 1 | |a Izquierdo-Sanchez, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Putignano, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a Carvalho-Gomes, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Posch, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Zanaga, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Girleanu, Irina |e verfasserin |4 aut | |
| 700 | 1 | |a Henrique, Mariana Moura |e verfasserin |4 aut | |
| 700 | 1 | |a Araújo, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Degre, Delphine |e verfasserin |4 aut | |
| 700 | 1 | |a Gustot, Thierry |e verfasserin |4 aut | |
| 700 | 1 | |a Sahuco, Iván |e verfasserin |4 aut | |
| 700 | 1 | |a Spagnolo, Elia |e verfasserin |4 aut | |
| 700 | 1 | |a Carvalhana, Sofia |e verfasserin |4 aut | |
| 700 | 1 | |a Moura, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandes, Diogo Ae |e verfasserin |4 aut | |
| 700 | 1 | |a Banales, Jesus M |e verfasserin |4 aut | |
| 700 | 1 | |a Romero-Gomez, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Trifan, Anca |e verfasserin |4 aut | |
| 700 | 1 | |a Russo, Francesco Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Stauber, Rudolf |e verfasserin |4 aut | |
| 700 | 1 | |a Berenguer, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Gonçalves, João |e verfasserin |4 aut | |
| 700 | 1 | |a Cortez-Pinto, Helena |e verfasserin |4 aut | |
| 700 | 1 | |a Castro, Rui E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JHEP reports : innovation in hepatology |d 2019 |g 5(2023), 5 vom: 20. Mai, Seite 100697 |w (DE-627)NLM306339021 |x 2589-5559 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2023 |g number:5 |g day:20 |g month:05 |g pages:100697 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jhepr.2023.100697 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2023 |e 5 |b 20 |c 05 |h 100697 | ||